Mechanisms of Androgen-Independent Prostate Cancer.
Prostate cancer is the second leading cause of cancer-related deaths among men in North America. Almost all prostate cancers begin in an androgen-dependent state, so androgen deprivation therapy is administered and results in improved clinical outcomes. However, over time, some cancerous cells are able to survive and grow during this treatment, resulting in androgen-independent prostate cancer. At this point, the disease is fatal, as there are no effective targeted therapies available. Most prostate cancer tumors require androgen receptor (AR) signalling for survival. During the progression to androgen-independence, this signalling cascade has been found to be altered at many levels within prostate cancers. Mechanisms that enhance AR signalling during androgen deprivation include: AR gene amplifications, AR gene mutations, changes in expression of AR co-regulatory proteins, changes in expression of steroid-generating enzymes, ligand-independent activation of AR via 'outlaw' pathways, and AR-independent pathways that become activated, termed 'bypass' pathways. One or more of these aforementioned changes can lead to prostate cancer cells to gain androgen-independent properties. Understanding the molecular alterations that occur during this process will allow for improved therapeutic strategies to target key molecules and pathways important for this progression.
Samuel Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, Toronto, ON, Canada; Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON, Canada.
Punit
P
Saraon
Samuel Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, Toronto, ON, Canada; Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON, Canada.
Andrei P
AP
Drabovich
Department of Surgery (Division of Urology), Mount Sinai Hospital , Toronto, ON, Canada.
Keith A
KA
Jarvi
Samuel Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, Toronto, ON, Canada; Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON, Canada; Department of Clinical Biochemistry, University Health Network, Toronto, ON, Canada.
Eleftherios P
EP
Diamandis
Androgen receptor; Androgen-independence; Androgen-independent prostate cancer; Castration-resistant prostate cancer; Prostate cancer; Prostate cancer progression
Cancer Res. 2009 Apr 15;69(8):3356-63
19351832
PLoS One. 2012;7(1):e30062
22279565
Virchows Arch. 2006 Feb;448(2):111-8
16328356
J Cell Biochem. 2004 Jan 1;91(1):13-25
14689577
Arch Biochem Biophys. 2003 Feb 1;410(1):134-40
12559985
Am J Pathol. 1993 Aug;143(2):390-400
7688182
J Pathol. 2002 Oct;198(2):237-44
12237884
J Biol Chem. 2003 Oct 31;278(44):42992-3000
12933816
J Biol Chem. 2003 Feb 14;278(7):5052-61
12441355
J Urol. 1974 Jan;111(1):58-64
4813554
Clin Transl Oncol. 2009 Jan;11(1):5-10
19155198
Endocr Relat Cancer. 2004 Mar;11(1):117-30
15027889
N Engl J Med. 2004 Oct 7;351(15):1488-90
15470210
Endocr Relat Cancer. 2010 Jan 29;17(1):F1-17
19779034
Cancer Invest. 2005;23(6):520-8
16203660
Prostate. 1996 Apr;28(4):251-65
8602401
Cancer Chemother Rep. 1966 Mar;50(3):125-8
5948714
Clin Cancer Res. 2009 May 15;15(10):3251-5
19447877
Biochem Biophys Res Commun. 2012 Jul 6;423(3):564-70
22695118
Int J Biochem Cell Biol. 2010 Jun;42(6):813-27
19931639
Cancer Res. 2001 Jun 1;61(11):4315-9
11389051
Genes Dev. 2000 Oct 15;14(20):2551-69
11040209
Cancer Res. 1999 Jun 1;59(11):2511-5
10363963
Lancet. 2003 Mar 8;361(9360):859-64
12642065
Proc Natl Acad Sci U S A. 1999 May 11;96(10):5458-63
10318905
Clin Chem. 2008 Dec;54(12):1951-60
18927246
Proc Natl Acad Sci U S A. 1992 Jul 15;89(14):6319-23
1631125
Prostate. 1989;14(2):103-15
2710689
Sci Transl Med. 2011 Mar 2;3(72):72ra17
21368222
Science. 1997 Mar 28;275(5308):1943-7
9072974
Nat Rev Cancer. 2001 Oct;1(1):34-45
11900250
Cancer Res. 2009 Oct 15;69(20):8141-9
19808968
Cancer Cell. 2010 Jun 15;17 (6):535-46
20541699
Proc Natl Acad Sci U S A. 2007 Dec 11;104(50):19983-8
18056640
J Clin Oncol. 2010 Aug 10;28(23):e408
20547989
J Histochem Cytochem. 1991 Jul;39(7):927-36
1865110
Cancer Res. 2003 Jan 1;63(1):149-53
12517791
Endocr Rev. 2007 Dec;28(7):778-808
17940184
Cancer Res. 1997 Jan 15;57(2):314-9
9000575
Cancer Res. 2009 Mar 15;69(6):2305-13
19244107
BJU Int. 2005 Jun;95(9):1327-35
15892826
Cancer Res. 2010 Feb 1;70(3):1256-64
20086173
Cancer Res. 2000 Feb 15;60(4):944-9
10706109
J Urol. 1992 Mar;147(3 Pt 2):798-803
1371552
PLoS One. 2013 Sep 23;8(9):e74775
24086370
Cancer Cell. 2008 Jun;13(6):519-28
18538735
J Cell Biochem. 2006 Oct 1;99(2):392-401
16639715
Oncogene. 2014 May 22;33(21):2790-800
23770851
Nat Rev Cancer. 2002 May;2(5):389-96
12044015
Nat Med. 1999 Mar;5(3):280-5
10086382
J Cell Biochem. 2004 Feb 15;91(3):483-90
14755679
RNA. 2008 Mar;14 (3):417-24
18174313
Cancer Res. 1994 Jun 1;54(11):2861-4
8187068
Int J Cancer. 2012 Apr 1;130(7):1521-31
21500190
Trends Endocrinol Metab. 1998 Oct 1;9(8):310-6
18406295
Cancer Lett. 2009 Feb 18;274(2):177-86
18657355
Int J Cancer. 1996 Jan 3;65(1):85-9
8543402
N Engl J Med. 1995 May 25;332(21):1393-8
7723794
Endocr Relat Cancer. 2009 Mar;16(1):155-69
19011039
Best Pract Res Clin Endocrinol Metab. 2008 Apr;22(2):373-88
18471793
Cancer Res. 2008 Jun 1;68(11):4447-54
18519708
Cancer. 1991 Jun 15;67(12):3057-64
1710537
Br J Cancer. 2003 Aug 4;89(3):552-6
12888829
Indian J Urol. 2008 Jul;24(3):309-12
19468459
Clin Chem. 2011 Oct;57(10):1366-75
21956922
Cancer Res. 1994 Oct 15;54(20):5474-8
7522959